What is the maximum dose of isosorbide mononitrate for treating hypertension?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Isosorbide Mononitrate is NOT Indicated for Hypertension Treatment

Isosorbide mononitrate should not be used as a primary or routine treatment for hypertension. This medication is not approved by the FDA for blood pressure management and lacks guideline support for this indication.

FDA-Approved Dosing (For Angina, Not Hypertension)

The FDA-approved maximum dose of isosorbide mononitrate extended-release is 240 mg once daily, though this is indicated for angina pectoris, not hypertension 1. The standard dosing progression is:

  • Starting dose: 30-60 mg once daily
  • May increase to 120 mg once daily after several days
  • Rarely, 240 mg may be required
  • Taken once daily in the morning 1

Why This Drug Is Wrong for Hypertension

Guideline Evidence Shows Different Indications

The most recent and authoritative guidelines—the 2022 AHA/ACC/HFSA Heart Failure Guidelines and 2025 AHA/ACC Hypertension Guidelines—do not recommend isosorbide mononitrate for hypertension 2, 3, 4, 5.

Isosorbide dinitrate (not mononitrate) is only recommended in combination with hydralazine for heart failure with reduced ejection fraction (HFrEF), particularly in African American patients who remain symptomatic despite optimal therapy 2, 3, 6, 3. The maximum dose for this indication is:

  • Isosorbide dinitrate: 120 mg total daily in divided doses (with hydralazine 300 mg daily) 2, 3

Hypertension Guidelines Recommend Other Agents

The 2025 AHA/ACC and 2024 ESC hypertension guidelines clearly recommend first-line agents for blood pressure control 4, 5:

  • ACE inhibitors or ARBs
  • Dihydropyridine calcium channel blockers
  • Thiazide/thiazide-like diuretics

Nitrates are only mentioned for acute hypertensive emergencies (intravenous nitroglycerin, maximum 20 mcg/min) in specific contexts like acute coronary syndrome or acute pulmonary edema 7, 8.

Research Evidence Is Weak and Contradictory

While some small studies explored isosorbide mononitrate for systolic hypertension, the evidence is insufficient:

  • A 2022 randomized controlled trial (58 patients, average age 77) found no significant benefit of sustained-release isosorbide mononitrate 40-60 mg for isolated systolic hypertension compared to placebo 9
  • Earlier open-label studies from 1997-2005 suggested possible benefits at doses of 30-120 mg daily, but these lacked rigorous controls 10, 11
  • A 2011 hemodialysis study showed blood pressure reduction with up to 120 mg daily, but this was in a highly specific population with unique pathophysiology 12

The most recent and highest quality study showed no benefit, making this an inappropriate choice for hypertension management 9.

Common Pitfalls to Avoid

  1. Do not confuse isosorbide mononitrate with isosorbide dinitrate—they are different drugs with different indications
  2. Do not use nitrates as monotherapy for chronic hypertension—they are not guideline-directed therapy
  3. Tolerance develops rapidly with continuous nitrate exposure, limiting long-term efficacy 1
  4. Contraindications include: concurrent phosphodiesterase-5 inhibitor use (sildenafil, tadalafil, vardenafil), hypotension, and severe volume depletion 13

What You Should Use Instead

For hypertension management, follow guideline-directed therapy 4, 5:

  • First-line: ACE inhibitor/ARB + calcium channel blocker or thiazide diuretic
  • Target blood pressure: 120-129 mmHg systolic in most adults
  • Combination therapy is preferred over monotherapy for most patients with confirmed hypertension (≥140/90 mmHg)

References

Related Questions

Should doxazosin be preferred over isosorbide mononitrate (IMDUR) for treating hypertension?
Should the dose of isosorbide mononitrate (isosorbide) 20 mg be reduced in a patient who develops hypotension?
Can isosorbide mononitrate cause hypotension?
For a patient with a history of stroke and high blood pressure, what oral dose and dosing schedule of isosorbide mononitrate should be used after the acute episode is stabilized?
Can isosorbide dinitrate be given to lower resistant hypertension?
Is there an interaction or adverse reaction when combining venlafaxine with Adderall (mixed‑amphetamine salts) after only two days of use?
What are the differences between hydroxyzine and cinnarizine for the prevention and treatment of motion sickness?
Should a young patient with fever, cough, nausea, diarrhea, influenza infection, negative SARS‑CoV‑2 test, normal white blood cell count with relative lymphopenia and neutrophilia be managed as an atypical respiratory infection?
Is the diarrhea in a patient taking venlafaxine who has insomnia and headache more likely a medication side effect rather than serotonin syndrome?
What is the most appropriate next step in evaluating painless quadriceps weakness?
What is the clinical utility and predictive strength of systemic inflammation indices (e.g., neutrophil‑lymphocyte ratio, systemic immune‑inflammation index) for cardiovascular disease risk assessment?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.